CymaBay Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.cymabay.com
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06060665
- Locations
- 🇺🇸
The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸University of California (UC) Davis Medical Center, Sacramento, California, United States
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT04620733
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇲🇽Consultorio de la Doctora Maria Sarai Gonzalez Huezo, Metepec, Mexico
🇺🇸UPMC Center for Liver Diseases, Pittsburgh, Pennsylvania, United States
Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CB-0406 100 mgDrug: CB-0406 200 mgDrug: CB-0406 800 mgDrug: CB-0406 1,000 mgDrug: Matched placeboDrug: CB-0406 400 mg
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04467684
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT03602560
- Locations
- 🇺🇸
Henry Ford Health System, Novi, Michigan, United States
🇺🇸Liver Institute at Methodist Dallas, Dallas, Texas, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03551522
- Locations
- 🇺🇸
CymaBay Research Site, Rollingwood, Texas, United States
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03369002
- Locations
- 🇺🇸
Vrg & Noccr, Knoxville, Tennessee, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Drug: MBX-8025 2 mg CapsuleDrug: MBX-8025 5 mg CapsuleDrug: MBX-8025 10 mg Capsule
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02955602
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States
🇺🇸Henry Ford Health System, Novi, Michigan, United States
🇨🇦Toronto Centre for Liver Disease, Toronto, Ontario, Canada
Study to Evaluate the Effects of MBX-8025 in Patients With HoFH
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Drug: MBX-8025 50 mg (Dose Escalation Period 1)Drug: MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)Drug: MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02472535
- Locations
- 🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦Montreal Heart Institute, Montreal, Quebec, Canada
🇫🇷Endocrinologie metabolisme et prevention cardiovasulaire, Institut E3M et IHU cardiometabolique (ICAN), Hôpital Pitié Salpêtrière, Paris, France
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
- Conditions
- HyperuricemiaGout
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02252835
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
- Conditions
- Gout
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT02063997